Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
P/E ratio for Repare Therapeutics Inc. (RPTX)
P/E ratio as of 2023: -3.28
According to Repare Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.28. At the end of 2022 the company had a P/E ratio of -21.23.
P/E ratio history for Repare Therapeutics Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.28 |
| 2022 | -21.23 |
| 2021 | -7.46 |
| 2020 | -23.70 |
| 2019 | -41.50 |
| 2018 | -34.05 |
| 2017 | -62.38 |